GC Pharma/Biocon Eye Low Price Strategy As Biosimilar Insulin Glargine Approved In Korea

GC Pharma/Biocon are set to adopt a low price strategy for their biosimilar insulin glargine, which has just received regulatory approval in South Korea, to better compete with rival products.